lovastatin has been researched along with Diabetic Retinopathy in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, D; Li, J; Ma, JX; Mott, R; Wang, JJ; Yu, Q; Zhang, SX | 1 |
| Bariciak, MD; Nichols, BD | 1 |
1 review(s) available for lovastatin and Diabetic Retinopathy
| Article | Year |
|---|---|
Cataracts in systemic diseases and syndromes.
Topics: Amiodarone; Cataract; Cataract Extraction; Diabetes Complications; Diabetic Retinopathy; Female; Humans; Lens, Crystalline; Lovastatin; Male; Neurofibromatosis 2; Propranolol; Syndrome | 1995 |
1 other study(ies) available for lovastatin and Diabetic Retinopathy
| Article | Year |
|---|---|
Systemic administration of HMG-CoA reductase inhibitor protects the blood-retinal barrier and ameliorates retinal inflammation in type 2 diabetes.
Topics: Animals; Blood-Retinal Barrier; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Drug Evaluation, Preclinical; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Intercellular Adhesion Molecule-1; Lipids; Lovastatin; Male; Mice; Mice, Inbred C57BL; NF-kappa B; Retina; Retinal Pigment Epithelium; Tight Junctions; Tumor Necrosis Factor-alpha | 2009 |